Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy

British Journal of Anaesthesia

Volumn 86, Issue 2, 2001, Pages 223-229

  Soriano, S G ^a   Sullivan, L J ^a   Venkatakrishnan, K ^b   Greenblatt, D J ^b   Martyn, J A J ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Children; Complications, epilepsy; Neuromuscular block, vecuronium

Indexed keywords

3 HYDROXIDE DESACETYLVECURONIUM; ANTICONVULSIVE AGENT; ATRACURIUM; CARBAMAZEPINE; DIMETHYLTUBOCURARINE CHLORIDE; DRUG METABOLITE; FENTANYL; HALOTHANE; ISOFLURANE; MUSCLE RELAXANT AGENT; NEUROMUSCULAR BLOCKING AGENT; NITROUS OXIDE; OROSOMUCOID; OXYGEN; PANCURONIUM; PHENYTOIN; PIPECURONIUM; ROCURONIUM; STEROID; THIOPENTAL; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; VECURONIUM;

ADOLESCENT; AGE; ANTICONVULSANT THERAPY; ARTICLE; BODY WEIGHT; BOLUS INJECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESISTANCE; ELECTROMYOGRAPHY; FEMALE; HUMAN; LONG TERM CARE; MALE; MUSCLE TWITCH; NEUROMUSCULAR TRANSMISSION; PRIORITY JOURNAL; TIME;

EID: 0035143397     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/86.2.223     Document Type: Article

References (35)

1. The evaluation and treatment of seizures
2. The effect of phenytoin on the magnitude and duration of neuromuscular block following atracurium or vecuronium
3. Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy
4. Hepatic blood flow and drug metabolism in patients on enzyme-inducting anticonvulsants
5. Antiepileptic drugs
6. Onset and duration of action of rocuronium in children receiving chronic anticonvulsant therapy
7. Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients
8. Decreased sensitivity to metocurine during long term phenytoin therapy may be attributable to protein binding and acetylcholine receptor changes
9. Drug binding to human alpha-l-acid glycoprotein in health and disease
10. Plasma protein binding of drugs after severe burn injury
11. Plasma binding and limitation of drug access to site of action
12. 2O, halothane anesthesia
13. Vecuronium kinetics and dynamics in anesthetized infants and children
14. High-performance liquid chromatography-electrochemical detection of vecuronium and its metabolites in human plasma
15. Pharmacokinetics of d-tubocurarine in patients with thermal injury
16. Differential effects of the anticonvulsants phenobarbital, ethosuximide, and carbamazepine on neuromuscular transmission
17. Phenytoin: Electrophysiological effects at the neuromuscular junction
18. The effect of acutely administered phenytoin on vecuronium-induced neuromuscular blockade
19. Acute in vitro neuromuscular effects of carbamazepine and carbamazepine-10-11-epoxide
20. Phenytoin-induced resistance to vecuronium
21. Interaction of rocuronium (ORG 9426) and phenytoin in a patient undergoing renal transplantation: A possible pharmacokinetic mechanism?
22. Resistance to metocurine-induced neuromuscular blockade in patients receiving phenytoin
23. Atracurium-induced neuromuscular block is not affected by chronic anticonvulsant therapy with carbamazepine
24. Chronic carbamazepine therapy does not influence mivacurium-induced neuromuscular blockade
25. Recovery from mivacurium-induced neuromuscular blockade is not affected by anticonvulsant therapy
26. Safety and efficacy of vecuronium in adolescent and children
27. Pharmacokinetic drug interactions with phenytoin
28. Pharmacokinetic drug interactions with phenytoin
29. Succinylcholine: Mechanism of fasciculations and their prevention by d-tubocurarine or diphenylhydantoin
30. Basic and clinical pharmacology of the acetylcholine receptor: Implication for the use of neuromuscular relaxants
31. Prolonged d-tubocurarine infusion and/or immobilization cause upregulation of acetylcholine receptors and hyperkalemia to succinylcholine in rats
32. Prolonged duration of succinylcholine in patients receiving anticonvulsants: Evidence for mild upregulation of acetylcholine receptors?
33. The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers
34. Disease-induced variations in plasma protein levels: Implications for drug dosage regiments
35. Elevated plasma alphal-acid glycoprotein levels: Lack of connection to resistance to vecuronium blockade induced by anticonvulsant therapy